Normunity
Putting Cancer's Secrets in Plain Sight
New Haven, United States · Founded 2020 · $140.0M raised
- Headquarters
- New Haven, Connecticut
- Employees
- 11–50
- Founded
- 2020
- Business Model
- B2B
- Website
- normunity.com
- Total Funding
- $140.0M
- Last Round
- $75.0M Series BJan 2025
- Rounds
- 2
About
Normunity is a clinical-stage biotechnology company developing novel anti-cancer biologics called immune normalizers, which target untapped biology at the tumor-immune interface. Founded on research from Yale School of Medicine's Lieping Chen lab, Normunity's lead program is advancing into clinical trials following a $75M Series B in January 2025. The company is headquartered in New Haven, CT with operations in Boston, MA.
Summary
Normunity is a Biotech company based in New Haven, United States, founded in 2020. It has raised $140.0M in total across 2 rounds, most recently a $75.0M Series B round in Jan 2025. Investors include Samsara BioCapital, Enavate Sciences and Canaan Partners.
Tech & App Stack
3 technologies & apps tracked
Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jan 2025
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Biopharmaceutical services company